Fosså, A., Molin, D., Bröckelmann, P. J., Schneider, G., Schnetzke, U., Linderoth, J., . . . Böll, B. (2025). Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG-NLG phase II BVB trial. HemaSphere, 9(3), . https://doi.org/10.1002/hem3.70099
Chicago-Zitierstil (17. Ausg.)Fosså, Alexander, et al. "Brentuximab Vedotin Monotherapy Is a Feasible and Effective Treatment for Older Patients with Classical Hodgkin Lymphoma Unsuitable for Curative Chemotherapy: Results from the Prospective GHSG-NLG Phase II BVB Trial." HemaSphere 9, no. 3 (2025). https://doi.org/10.1002/hem3.70099.
MLA-Zitierstil (9. Ausg.)Fosså, Alexander, et al. "Brentuximab Vedotin Monotherapy Is a Feasible and Effective Treatment for Older Patients with Classical Hodgkin Lymphoma Unsuitable for Curative Chemotherapy: Results from the Prospective GHSG-NLG Phase II BVB Trial." HemaSphere, vol. 9, no. 3, 2025, https://doi.org/10.1002/hem3.70099.